Get started
Author

Rebecca E. Mercer

Observed names: Mercer, Rebecca, Mercer, Rebecca E, R.E. MERCER, R.E. Mercer, Rebecca E Mercer, Rebecca Mercer
Observed institutions: St. Michael's Hospital, Sunnybrook Health Science Centre, University of Alberta, Canadian Cancer Society, University of Toronto, Cancer Care Ontario, Canadian Centre for Applied Research in Cancer Control, Sunnybrook Hospital, Sunnybrook Research Institute, Ontario Health
ORCID: 0000-0002-9264-7797
Observed ORCID: 0000-0002-9264-7797
OpenAlex ID: A5035467493
The role of NPY in hypothalamic mediated food intake
2011 · Rebecca E. Mercer, Melissa J.S. Chee, et al. · Frontiers in Neuroendocrinology · 200
Loss of Magel2, a Candidate Gene for Features of Prader-Willi Syndrome, Impairs Reproductive Function in Mice
2009 · Rebecca E. Mercer, Rachel Wevrick · PLoS ONE · 107
PDF
Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene Magel2
2009 · Rebecca E. Mercer, Erin M. Kwolek, et al. · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · 106
Adaptive Search Using a Reproductive Meta‐plan
1978 · R.E. MERCER, J.R. SAMPSON · Kybernetes · 92
Magel2 Is Required for Leptin-Mediated Depolarization of POMC Neurons in the Hypothalamic Arcuate Nucleus in Mice
2013 · Rebecca E. Mercer, Sheldon D. Michaelson, et al. · PLoS Genetics · 91
PDF
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
2020 · Kelvin Chan, Seungree Nam, et al. · BMJ Open · 55
PDF
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
2024 · Joseph C Del Paggio, Rohini Naipaul, et al. · The Lancet Oncology · 27
Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups
2020 · Rebecca E. Mercer, Alexandra Chambers, et al. · Value in Health · 17
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
2021 · Wei Fang Dai, Vanessa Arciero, et al. · Current Oncology · 14
PDF
Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives
2020 · Marc Clausen, Chloe Mighton, et al. · CMAJ Open · 13
PDF
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
2022 · Wei Fang Dai, Jaclyn M. Beca, et al. · JAMA Network Open · 12
PDF
Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada
2020 · Wei Fang Dai, Jaclyn Beca, et al. · International Journal of Cancer · 11
PDF
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
2024 · Pam Takhar, Marc Geirnaert, et al. · Current Oncology · 10
PDF
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
2021 · Wei Dai, Erica Craig, et al. · Current Oncology · 10
PDF
Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data
2024 · Brandon Lu, Erind Dvorani, et al. · Value in Health · 9
PDF
Energy homeostasis in Prader–Willi Syndrome: How clinical research informs studies of animal models of genetic obesity
2012 · Rebecca E. Mercer, Rachel Wevrick · American Journal of Medical Genetics Part A · 8
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group
2022 · Wei Dai, Claire de Oliveira, et al. · Current Oncology · 6
PDF
Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
2023 · Brandon Lu, Wei Fang Dai, et al. · Cancer Medicine · 5
PDF
Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
2025 · Kelvin Kar-Wing Chan, Pam Takhar, et al. · BMJ Open · 4
Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study
2025 · Caroline E. Muñoz, Wei Fang Dai, et al. · International Journal of Cancer · 4
PDF
Impact of rarity on Canadian oncology health technology assessment and funding
2020 · James Keech, Wei Fang Dai, et al. · International Journal of Technology Assessment in Health Care · 4
Cost-effectiveness analysis of bevacizumab biosimilars for metastatic colorectal cancer: A comparative study using real-world data.
2023 · Brandon Lu, Erind Dvorani, et al. · JCO Oncology Practice · 3
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
2023 · Ambica Parmar, Wei Fang Dai, et al. · Current Oncology · 3
PDF
Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal Cancer
2024 · Caroline Muñoz, Jaclyn M. Beca, et al. · Journal of the National Comprehensive Cancer Network · 2
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario
2021 · Rohini D. Naipaul, Rebecca E. Mercer, et al. · Current Oncology · 2
PDF
Works count: 34
Citation count: 814
H-index: 11
I10-index: 14
Year
Topic
Type